Abstract-D,, a subtype of the dopamine receptors, is widely distributed in the nervous system and has been shown to be positively coupled to adenylate cyclase. Using a combination of in vitro receptor autoradiographic and in situ hybridization techniques, the present study examines the co-distribution of D, receptor binding sites and D, receptor messenger RNA in adjacent rat brain sections. D, receptor binding sites were labeled using the selective antagonist ['H]SCH23390 (4.6 nM) in the presence of 1 pM ketanserin, while the D, receptor messenger RNA was visualized with a '?I-labeled riboprobe corresponding to a region between transmembrane domains III and VI of the rat D, receptor (bp 3833843). Analysis of serial sections suggested a good agreement between D, receptor binding and messenger RNA in several brain regions, including the paleocortex, caudate-putamen, nucleus accumbens, amygdala and suprachiasmatic nucleus. Marked discrepancies between D, receptor binding and messenger RNA were observed in other brain regions including the entopeduncular and subthalamic nuclei, substantia nigra (pars reticulata), hippocampus and cerebellum. While technical considerations may contribute to these results, much of the discordance between the distributions is likely due to the differential localization D, receptor messenger RNA in cell bodies and receptor binding sites on fibers and may provide insights into receptor synthesis, transport and membrane insertion. In the basal ganglia, for instance, D, receptors are synthesized in the striatum and are either transported to efferent projections in areas such as the substantia nigra, or remain localized in striatal cells bodies. Ibotenic acid lesions in the striatum are consistent with these conclusions and demonstrate a coordinate loss of D, receptor binding and messenger RNA in the caudatcputamen that is accompanied by a degeneration of fibers projecting to substantia nigra and a loss of D, binding in the pars reticulata. Neurons in the dentate gyrus and in the granular layer of the cerebellum, on the other hand, synthesize D, receptors and transport them entirely to either their dendritic or axonal fields, respectively, in the molecular layer.
Dopamine receptors in the CNS can be differentiated into two subtypes referred to as D1 and Dr. Because of their clinical relevance in Parkinson's disease and schizophrenia, a great deal of research has been generated to localize these receptor sites in the CNS 10.'*,3g examine their regulation following drug treatment and lesions5~'3*M*31 and study the second messenger systems to which they are coupled.36 The D, dopamine receptor subtype is widely distributed in the CNS,2,4*16 can be upregulated by dopamine receptor antagonists, such as (R)-( + )-8-chloro-2,3,5-tetrahydro-3-methyl-5-phenyl-lH-3-benzazepin-7-ol (SCH23390),'**' and is positively coupled to adenylate cyclase via a G, protein. 6,32 D, receptors, on the other hand, are abundant in the basal ganglia and pitutTo whom correspondence should be addressed. Abbreviations: EDTA, ethylenediaminetetra-acetate; S-HT, 5hydroxytryptamine; SCH23390, (R)-( +)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-l~-3-~~ze~in-7-01; SCH23982, (SR)18-iddo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-lH-3-benzazepin-7-01; SSC, sodium chloride-sodium citrate buffer. itary,39.12 are upregulated following 6-hydroxydopamine lesions'3*3' and chronic haloperidol treatment,25 and are either uncoupled or negatively coupled to adenylate cyclase. 29 The recent cloning of the D, receptor'7~30~37*41 has provided a new means of examining issues of receptor structure, regulation and function. The D1 receptor is a 446-amino acid protein and has a 40-M% amino acid identity with other cloned catecholamine receptors including the D2 receptor. Based on hydrophobicity analysis, the receptor appears to have seven transmembrane domains and contains no introns within its protein coding region. It differs from the D2 receptor which contains multiple introns and a long third cytosolic loop. I' Transfection of the D, clone into COS cells produced the expression of D,-specific binding (PHlSCH23390) and a positive coupling to adenylate cyclase.
The goal of this study is to provide a qualitative examination of the D, receptor mRNA and binding site distributions in the brain using a combination of in situ hybridization and receptor autoradiographic
techniques. An obvious concern in such an analysis is that receptor binding sites and mRNA may be localized on different neuronal elements. Receptor binding is localized on both cell bodies and fibers, while mRNA is thought to be localized primarily in cell bodies. Therefore, while regions of concordance would be expected since the D, receptor mRNA and binding sites are products of the same gene, some anatomical discordance would not be surprising due to differential localization on neuronal fibers. Such a lack of correspondence between receptor binding and mRNA, in fact, suggests receptor transport within a neuron, something with has previously only been effectively demonstrated with lesion studies. ',38 Given the complexity of this task, this study focuses on regions of the CNS with better known circuitry, such as the hippocampus, basal ganglia and cerebellum, with a minimal discussion of other regions of the forebrain and midbrain. To aid in determining whether the differences observed in receptor mRNA and binding are due to a differential localization on neuronal fiber, ibotenic acid lesions were performed to selectively destroy cell bodies24 and trace their degenerating terminals.
EXPERIMENTAL PROCEDURES

Tissue preparation and incubarion medium for receptor binding srudies
Adult male SpragueDawley rats (Charles River, 200-250 g) were killed by decapitation and their brains were quickly removed and frozen in liquid isopentane (-30°C 30s) . Frozen tissues were sectioned on a Bright cryostat (2Opm), thaw-mounted on precleaned and subbed microscope slides, and stored at -80°C. Immediately prior to using the tissue, the slide-mounted sections were gradually brought to room temperature and incubated (90 min, 22°C) with 20&400~1 of the selective D, antagonist [3H]SCH233908~22 (71.3 Ci/mmol) in 50 mM Tris buffer (pH 7.5 at 25°C) containing 0.1% ascorbic acid, 120 mM NaCl, 5 mM KC1 and 1 mM MgCl, The labeling concentration of [3H]SCH23390 (4.6 nM) was chosen to correspond to three times the Kh value of the Jigand*' and results in a 75% receptor occupancy. As SCH23390 has been reported to bind serotonergic sites (5-HT,), 1 PM ketanserin, a selective 5-HT, antagonist, was added to all ['H]SCH23390 binding studies.
Following a 90-min incubation period,the slides were drained, washed in four 4-min consecutive 250m1, 50mM Tris (pH 7.6, 4°C) washes containing 0.1% ascorbic acid, 120 mM NaCl, 5 mM KC1 and 1 mM MgCl, All slides were then quickly dipped in 250 ml distilled water (4°C) and dried with a portable hair dryer set to "cool". Nonspecific binding was evaluated by treating a parallel set of slides with the same concentration of tritiated Jigand with a 1 FM final concentration of unlabeled SCH23390. The slides were then apposed to tritium-sensitive Hypertilm (Amersham) for four weeks. The Hype&m was exposed at room temperature, developed in 19"C) , agitated in 2% acetic acid (30 s), fixed in Kodak Rapidfix (5 min), and washed under running water (30min). Anatomical structures were determined using Nissl-stained sections in conjunction with the atlas of Paxinos and Watson." In situ hybridization Slides adjacent to those used for autoradiographic mapping of D, binding sites were directly removed from storage at -80°C and placed into 4% formaldehyde for 60 min (22°C) prior to being processed for I/I SIIL( :rybrrdtlation.28,"5. 40 Following three 5-min rinses in phosphatebuffered saline (pH 7.4), sections were treated with proteinase K (1 p-g/ml in 100 mM Tris, pH 8.0. 50mM EDTA) for 10 min at 37°C. Slides were then rinsed in water. followed by 0.1 M triethanolamine @H 8.0), and treated with a mixture of 0. I M triethanolamine (pH 8.0) and acetic anhydride (400: 1, vol:vol) with stirring for 10 min. 'The sections were then rinsed in 2 x sodium chloride sodium citrate buffer (SSC) (300 mM NaCI, 30 mM sodium citrate. pH 7.2) for 5 min, dehydrated through graded alcohols. ;md allowed to air dry.
Brain sections were hybridized with a [?3]UTP-labeled 480-bp riboprobe generated to the region of the rat D, receptor spanning transmembranes III-VI (bp 383 843). cRNA probes generated with a pGEM transcriptional vector were diluted in hybridization buffer (75% formamide, 10% dextran sulfate, 3 x SSC. SOmM Na,PO, (pH 7.4). I x Denhardt's, 0.1 mg/ml yeast tRNA, 0.1 mg/ml sonicated, denatured salmon sperm DNA, 1OmM dithiothrietol) to result in a final concentration of 2 x 10hd.p.m./30~1. Volumes of 30 and 50~1 of diluted probe were applied to coronal and horizontal sections. respectively.
After hybridization (overnight, 55'C) the slides were rinsed in 2 x SSC (5 min) and treated with RNase A (200 pug/ml in 1OmM Tris, pH 8.0, and 0.5 M NaCl) for 60min at 37°C. Subsequently, sections were rinsed m 2 x SSC for 10 min (22°C). I x SSC for 10 min (22 C), 0.5 x SSC at 55°C for. 60 mm, 0.5 x SSC at room temperature for IO min. and finally dehydrated in graded alcohols and air dried. Sections were then either exposed to Kodak XAR-5 X-ray film for three to 10 days and developed, or dipped in Kodak NTB-2 emulsion and stored at 4'C prior to development 14 days later.
Ibotenic acid lesions
Ten male Sprague-Dawley rats (200-25Og) were anesthetized and placed in a Kopf stereotaxic apparatus. To ensure that the right rostra1 caudate-putamen was completely ablated, ibotenic acid (2.0 pg/pl) dissolved in phosphate-buffered saline was infused at three different coordinates in the caudateputamen using a 30-gauge cannula. With skull flat, the coordinates were B + 2.0/2.5/5.5, B + 1.0/3.0/5.5 and B-0.4/4.0/5.5 corresponding in millimeters to the anterior-posterior/lateral/and ventral planes as illustrated in the atlas of Paxinos and Watson.33 An infusion of 1 pl was given over a time interval of 2 min at each site and the cannula was allowed to remain in place for 5 min prior to removal. Fourteen days following the lesion, animals were killed by decapitation and their brains were frozen as described above. Brains were sectioned and processed for in situ hybridization and receptor autoradiography as described above. The extent of neuronal cell loss was evaluated with Nissl-stained sections and reference to the atlas of Paxinos and Watson.?' "Sense"-strand control
To assess whether the in situ signal reflected specitic hybridization to the D, receptor mRNA, a "sense''-strand control study was performed whereby a series of paired, adjacent sections was divided into two sets. One set of slides was treated according to the in situ protocol described above, while the second set was treated identically, except that the cRNA probe used in the hybridization mixture was ["S]UTP labeled sense-strand RNA.
Materials
[3H]SCH23390 was purchased from New England Nuclear and the unlabeled SCH23390 was a kind gift from Dr James Woods, University of Michigan, Ann Arbor, U.S.A. Ibotenic acid was purchased from Vachon Natural Products. Washington. Within the telencephalon, the highest levels of D1 receptor binding and mRNA are observed in the basal ganglia. In the caudate-putamen (Fig. lA,D ) D, receptor binding is densest in the head of the caudate-putamen with a rostral-to-caudal gradient observed. In addition, there are medial-lateral differences, with the densest binding found in the dorsomedial and ventrolateral portions of this nucleus. D1 receptor mRNA (Fig. lB,E ) appears more uniform in the caudateputamen, with somewhat higher levels observed ventrolaterally.
Ventrally in the nucleus accumbens, dense levels of DI receptor binding and mRNA are observed particularly in the shell and extend into the core (Fig. lD,E ). Both D, receptor binding and mRNA show a rostra1 to caudal gradient in the nucleus accumbens, with the highest level of D, receptors observed rostrally. The olfactory tubercle similarly demonstrates high levels of D, receptors, with the D, receptor mRNA levels (Fig. lB,C) exceeding those observed in the caudate-putamen and nucleus accumbens.
A region of discordance between D1 receptor mRNA and D, receptor binding is the globus and ventral pallidum ( Fig. 2A,B) . In the globus pallidus, a region with major projections from the striatum, there are low levels of D, receptor binding with moderate levels observed in the ventral pallidurn. In contrast, only a few cells of either the globus or ventral pallidum show D, receptor mRNA. Similarly in the septum, moderate levels of D, receptor binding are observed in the lateral nucleus with dense binding along its outer boundary, yet little D, receptor mRNA can be detected. The medial nucleus of the septum also shows a low level of D, receptor binding and no D, receptor mRNA, suggesting an absence of receptor synthesis in this region.
Within the hippocampal formation and dentate gyrus, D, receptor binding is moderate to low, with binding observed in the molecular layer of the dentate gyrus and in the stratum moleculare of the hippocampal formation (Fig. 2C) . Interestingly, D1 receptor mRNA is localized in the granular cell layer of the dentate gyrus and no D, receptor mRNA could be detected in the hippocampal formation (Fig. 2D) . This suggests both a transport of D, receptors within dentate gyrus and an extra-hippocampal projection to the stratum moleculare of the hippocampus.
The amygdaloid complex, a region with varying densities of D, receptor binding, shows a good correspondence between D, receptor binding and D, receptor mRNA (Fig. 3A,B) . The basolateral, lateral and central nuclei show low levels D, receptor mRNA and a moderate amount of D, binding (Fig.  3) . Similarly, moderate to dense levels of D, binding and mRNA appear co-localized in the cortical and basomedial amygdaloid nuclei (Fig. 3A,B) .
Diencephalon
The vast majority of the nuclei of the diencephalon show only low levels of D, receptor binding. Within the hypothalamus, low levels of D, binding are observed in most nuclei (Fig. 2C ) with somewhat higher levels in the arcuate nucleus. Only the suprachiasmatic nucleus of the hypothalamus shows moderate to dense D, binding ( Fig. 2A) . Similarly, D, receptor mRNA is undetectable in most of the hypothalamic nuclei with low to moderate levels observed only in the suprachiasmatic nucleus (Fig. 2B) . More dorsally, the thalamus shows only low levels of D, receptor binding in most nuclei with the habenula demonstrating moderate levels. Di receptor mRNA is undetectable in most of the thalamus.
The entopenduncular nucleus, a region receiving projections from the striatum, shows dense levels of D, receptor binding and no D, receptor mRNA (Fig.  4A,B) . Such a marked discordance between D, receptor binding and mRNA suggests that the dopaminergic binding observed in this nucleus is localized on striatal projections. There is dense D, receptor labeling in the caudate-putamen that extends to the entopeduncular nucleus and substantia nigra, as can be Seen from Fig. 4A . In fact, the D, containing fibers appear to course through the internal capsule and terminate in the substantia nigra. By comparison, D, receptor mRNA (Fig. 4B ) is observed only in the caudate-putamen which likely contains the cells of origin, Similarly, the subthalamic nucleus, a region receiving projections from the globus pallidus, also demonstrates dense D, receptor binding and no D, mRNA suggesting that the binding sites are localized on fibers.
Mesencephalon
In the midbrain, low levels of D, receptor binding are observed in the interpeduncular nucleus, periaqueductal gray, raphe nuclei, inferior colliculus and medial geniculate, with the superior colliculus demonstrating a moderate density of receptor binding (Fig. 5A) . Within the dopaminergic cell groups, low levels of D, receptor binding can be observed in the ventral tegmental area and the pars compacta of the substantia nigra, while dense D, binding is found in the pars reticulata of the substantia nigra ( Figs 4A,  5A ). Despite the presence of D, receptor binding, no D, receptor mRNA could be detected in the substantia nigra, ventral tegmental area, superior and inferior colliculi, periaqueductal gray, raphe or medial geniculate nucleus (Figs 4B , 5B).
Cerebellum
Because of its precise lamination, the cerebellum, like the hippocampus, is an excellent tissue for examining receptor localization. D, receptor binding is predominantly in the molecular layer of the cerebellum (Fig. 5C) , where low to moderate levels are observed. This layer of the cerebellum receives intrinsic projections from the granular cell layer where low to moderate Ievels of D, receptor mRNA can be localized (Fig. 5D ).
"&We"-strand controls
No specific hybridization was observed with sea tions labeled with the sense-strand probe, while the antisense riboprobe showed specific hybridization (data not shown).
Ibotenic acid lesions
The ibotenic acid lesions were restricted to the caudateputamen and primarily damaged the head and the rostra1 portion of the body of the cau~t~u~rnen.
Areas of cellular death, as sterns by Nissl staining, corresponded precisely to regions of D, receptor binding and mRNA loss (Fig. 6A,B) . The coordinate and nearly complete loss of both D, binding and mRNA suggests that the majority of D, receptors are localized in cell bodies in the A good correspondence between D, receptor binding and mRNA was found in areas such as the paleocortex, caudate-putamen, nucleus accumbens, olfactory tubercle, endopiriform nucleus, suprachiasmatic nucleus and amygdala. In addition, there appears to be a correlation in the relative abundance of both D, receptor binding and mRNA, such that regions of high receptor binding generally demonstrate high levels of D, receptor mRNA, while areas of low receptor binding demonstrate little or no detectable D, receptor mRNA. The amygdaloid complex is a particularly good example of such a correspondence, with specific nuclei displaying varying levels of D, receptor binding which correlated precisely to the relative amounts of D, receptor mRNA found in these areas.
Similarly, within the dopaminergic terminal fields of the basal ganglia, high levels of both D, receptor mRNA and binding are observed. In the nucleus accumbens, dense levels of D, receptor binding are seen in the shell and extend to form islands of very dense binding in the core of the nucleus. A gradient of D, binding is also seen with binding levels higher in the more rostra1 extent of the nucleus accumbens. D1 receptor mRNA is similarly localized in the accumbens with higher levels observed in the rostra1 extent, and patches of very dense receptor mRNA are observed. In the caudate-putamen, no obvious rostral to caudal gradient in mRNA levels could be detected, while a rostra1 to caudal gradient in receptor binding was seen in this and in other studies.3Jo,23 The D, receptor mRNA distribution within the caudate-putamen is not homogeneous, however, with higher levels observed in the dorsomedial and ventrolateral portions of the nucleus-regions that correspondingly have higher amounts of D, receptor binding. The olfactory tubercle, a third major dopaminergic terminal field, has both high levels of D, binding and mRNA.
Despite an overall good correspondence in D, receptor binding and mRNA in the rostra1 forebrain, several regions in the CNS fail to show such a relationship. A lack of correspondence can be manifest in one of two ways: either the localization of D1 receptor binding sites but no D, receptor mRNA, or the inverse, a visualization of D, receptor mRNA but no D, receptor binding. Examples of each type of discordance are observed and may be the result of several factors depending on the brain region involved.
Among the technical considerations that may contribute to this discrepancy in receptor binding and mRNA is ligand and probe selectivity. More specifically, the ligand or riboprobes chosen may label receptors other than D, thereby contributing to a lack of correspondence. While a consideration, it is an unlikely factor, as [3H]SCH23390 has been reported to be a highly selective D, antagonisP* and any 5-HTz receptor effects it may have should hale been blocked with the addition of 1 PM ketanserin used in the present study. With regard to the selectivity of the riboprobe, the D, receptor is approximately 40% homologous to the D2 receptor and the other carecholamine receptors that have been cloned. Given such a homology, the conditions used here should produce a selective hybridization to the D, receptor and studies from our laboratory have, in fact, demonstrated that the D, and DZ receptor mRNA distributions can be easily differentiated in the CNS using this riboprobe and these hybridization conditions (unpublished observations). However, we cannot rule out the possibility that this riboprobe may hybridize to a yet uncloned receptor or a variant of the D. receptor.
A second factor that may contribute to a lack of correspondence is that of sensitivity. This may be an issue in areas with a low density of D, receptors, such as most of the nuclei of the hypothalamus and thalamus, inferior colliculus, medial septum, interpeduncular nucleus, periaqueductal gray, raphe and ventral tegmental area. These regions contain low levels of D, receptor binding and no detectable mRNA, suggesting a possible lack of sensitivity with present in situ hybridization techniques.
A third technical factor that may influence these results is that of differential quenching of the isotopes used to label the binding sites and mRNA. Clearly, ['H]SCH23390 is differentially quenched in the brain, influencing the grain densities observed in various regions. As 35S-labeled riboprobes are stronger beta emitters, differential quenching is less of a problem, but can still contribute to the results. An iodinated ligand could have been used to label the D, binding sites; however, differential quenching between 35S and "'1 would still need to be considered. Furthermore, no significant anatomical differences have been observed between D, binding sites labeled with 3, 4, ( branes affecting neuronal excitability and specificity. Comparison of D, receptor binding and mRNA in the nigrostriatal system suggests that striatal neurons can synthesize D, receptors which are either transported along their fiber projections, or remain localized within the cell soma itself. This is probably not the case in other brain regions, such as the dentate gyrus and cerebellum. Neurons in these brain areas likely synthesize the D, receptor in their cell bodies and transport them mainly to either their dendritic (dentate gyrus) or axonal (cerebellum) fields as evidenced by the differential localization of D, receptor mRNA in the granular cell layers and D, binding in the molecular layers of both the dentate gyrus and cerebellum.
Within the hippocampal formation, D, receptor binding is found predominantly in the molecular layer, but no D1 mRNA is detected in the pyramidal cell layer, suggesting an extra-hippocampal source, such as cells in the entorhinal cortex that are known to terminate in the molecular layer of the hippocampus.
Though by no means complete, this analysis provides a better understanding of the dopamine receptor anatomy in terms of both its circuitry and cellular elements. While the use of receptor autoradiography has been invaluable in understanding the distribution of receptor binding sites, it cannot easily dissociate which binding sites are localized on cell bodies or fibers. Its combination with in situ hybridization techniques provides a new means of visualizing potential circuits and the differential cellular transport of receptors. The sensitivity of such an analysis largely depends on the anatomical substrate involved, with regions of discrete receptor binding, such as the suprachiasmatic nucleus, or laminated brain areas, such as the cerebellum, hippocampus and olfactory bulb being more amenable for this analysis. Similarly, well-defined circuits, such as the nigrostriatal system are far easier to examine relative to other brain areas.
In addition to long striatonigral projections, D, receptors are apparently localized within local circuits. The co-localization of D, receptor mRNA and binding in discrete nuclei of the amygdala and the suprachiasmatic nucleus, for example, suggest that the D, binding sites in these areas are either found on cell bodies or are on short or intrinsic projections. It is conceivable, however, that despite such a codistribution, the D, receptor mRNA and binding may not be localized in the same cells with, for example, the D, binding on terminals of one population of cells and the mRNA on another within the same nuclei. While it is difficult at present to determine the exact nature for such a co-localization, the use of electron microscopy and immunohistochemistry should be able to differentiate these possibilities.
What remains unclear, however, is which sites are functional. Receptor sites in long axonal projections may not be coupled to second messenger systems and unable to mediate physiological responses. While nascent receptors may be able to bind a ligand, they may not be functional until they have been inserted into terminals or dendritic membranes. Clearly, the present results need to be combined with microinjection studies to gain a better understanding of the anatomical circuitry and physiology. Future studies combining these techniques with other anatomical methods of visualizing second messengers or phosphinositide tumove?
will also be important in resolving these biological issues.
Comparison of D, receptor mRNA and binding similarly suggests that the D, receptor is also differentially transported within neurons of the CNS.*' In the zona incerta, for example, high levels of D, receptor
